NEW YORK, Nov. 15 (GenomeWeb News) - Shares in Tripos were up 21 percent at $5.46 in mid-afternoon trading as investors cheered news of an extended multimillion-dollar software license agreement with Pfizer.
The companies initially announced a wide area network partnership in January 2001 that Pfizer employ a "broad array" of Tripos' drug-discovery software tools, including the SYBYL and UNITY programs.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?Login Now.
Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.
The New York Times reports on the shifting interpretations of what some genetic variants mean over time.
In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.
MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.